The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Phase 3 Study Supports Use of Teprotumumab for Thyroid Eye Disease
October 14th 2019Raymond Douglas, MD, PhD, professor of ophthalmology and director of the Orbit and Thyroid Eye Disease Center at Cedars-Sinai, discusses results of the phase 3 OPTIC study and what a potential approval of teprotumumab would mean for patients and physicians.